Clinical Trials Logo

Filter by:
NCT ID: NCT01559090 Completed - Clinical trials for Systemic Lupus Erythematosus

Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

Start date: April 20, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI-546 in Japanese SLE patients.

NCT ID: NCT01558271 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Start date: March 2012
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.

NCT ID: NCT01557244 Completed - Clinical trials for Urinary Bladder, Neurogenic

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Start date: July 2, 2012
Phase: Phase 3
Study type: Interventional

The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old. This is done by finding out how well it works, what the body does to fesoterodine, what side effects are experienced and the safety of fesoterodine. It will be compared with the medicine oxybutynin, which is already available for treating the condition.

NCT ID: NCT01556438 Completed - Multiple Myeloma Clinical Trials

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Start date: July 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and effect on the body of Tabalumab (LY2127399) in combination with bortezomib and dexamethasone in Japanese participants with relapsed or refractory multiple myeloma (MM).

NCT ID: NCT01555151 Completed - Asthma Clinical Trials

Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma

Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy, safety and pharmacokinetics of Mometasone furoate delivered via Concept1 device or Twisthaler® device in adult and adolescent patients with persistent asthma.

NCT ID: NCT01553656 Completed - Cancer Clinical Trials

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Start date: February 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics, pharmacogenomic (PGX) and preliminary efficacy following daily oral doses of cabozantinib (XL184) in Japanese patients with advanced or metastatic solid tumors. Also, the effect of XL184 in the treatment of non-small cell lung cancer (NSCLC) patients with various activating mutations will be evaluated at the recommended Phase 2 dose.

NCT ID: NCT01553565 Completed - Colorectal Polyps Clinical Trials

Prospective Comparison of Cold Polypectomy and Conventional Polypectomy for Small Colorectal Polyps in Patients Taking Antithrombotic Agents

Start date: March 2012
Phase: N/A
Study type: Interventional

1. Background: The ideal method to remove small colorectal polyps in patients who are taking antithrombotic agents is unknown. 2. Aim: The aim of this study is to evaluate postpolypectomy bleeding and the complete retrieval rate after the removal by colon snare transection without electrocautery for small polyps in patients who are taking antithrombotic agents. 3. Design: A prospective, consecutive study. 4. Setting: Municipal hospital outpatients. 5. Interventions: Polypectomy by cold snare technique (Cold polypectomy) was performed for colorectal polyps up to 10 mm in diameter in patients who continue to take antithrombotic agents. The primary outcome measure was bleeding within two weeks after polypectomy. Secondary outcome measure was the complete retrieval rate of colorectal polyps based on the pathological examination.

NCT ID: NCT01552057 Completed - Fibromyalgia Clinical Trials

A Study of Duloxetine in Fibromyalgia

Start date: March 2012
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the effectiveness and safety of duloxetine in participants with fibromyalgia.

NCT ID: NCT01551602 Completed - Osteoporosis Clinical Trials

Clinical Study of AK159 in Healthy Postmenopausal Women

Start date: March 2012
Phase: Phase 1
Study type: Interventional

The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.

NCT ID: NCT01551069 Completed - Clinical trials for Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion

Start date: March 2012
Phase: Phase 3
Study type: Interventional

Primary Objective: - To investigate the efficacy on skin manifestation of 16 weeks treatment of once daily regimen of hydroxychloroquine sulphate (HCQ) in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active skin manifestation (CLASI [Cutaneous Lupus Erythematosus Disease Area and Severity Index] activity score is ≥4) concomitant treatment with or without corticosteroid. Secondary Objectives: - To evaluate the efficacy on skin manifestation and the safety of 16 weeks treatment of once daily regiment of HCQ versus placebo as the reference group in patients with CLE and SLE with active skin manifestation (CLASI activity score is ≥4) concomitant treatment with or without corticosteroid. - To investigate the safety of 16 weeks treatment of once daily regiment of HCQ in patients with CLE and SLE with active skin manifestation concomitant treatment with or without corticosteroid. - To investigate the safety and efficacy of 52 weeks long-term treatment of once daily regimen of HCQ in patients with CLE and SLE - To investigate the influence of the dose reduction of corticosteroid on CLE and SLE patients treated with HCQ concomitant with corticosteroid - To investigate efficacy of once daily regimen of HCQ on systemic symptoms, musculoskeletal symptoms and immunological parameters in SLE patients.